Barbara Pruitt, Kauffman Foundation
Diverse leaders in translational medicine are attending second annual Forum on May 13 – 15 in Philadelphia; registration deadline is approaching
KANSAS CITY, Mo. (April 2, 2009) – The second annual Translational Medicine Alliance Forum is drawing interest from a diverse mix of organizations and leaders interested in moving medical discoveries from the lab to the market. Founded by the Kauffman Innovation Network and the Translational Medicine Alliance, the Forum will take place May 13-15, 2009, in Philadelphia, Pa, at the Loews Philadelphia Hotel.
The primary goal of the Translational Medicine Alliance Forum 2009 is to develop a more effective model to enable translational medicine by connecting leading investigators and entrepreneurs with collaborators from the philanthropic, investment and corporate communities. Attendees will have the opportunity to meet with numerous organizations funding translational programs, develop commercial, clinical and R&D partnerships, discover novel translational research approaches and exchange ideas with leaders from the major medical philanthropies, federal research/regulatory groups, pharmaceutical and biotech companies, venture funds and the top medical research institutions.
"This is the only meeting of its kind where luminaries in all areas of the translational world connect to explore new methods for moving innovations to market," said Lesa Mitchell, vice president of Advancing Innovation at the Kauffman Foundation. "People who attend this forum will meet, debate and brainstorm with scientists, industry and philanthropy leaders, and this is how real innovation happens."
Participants at the Translational Medicine Alliance Forum include Astra Zeneca, Howard Hughes Medical Institute, Bayer, Institute for Pediatric Innovation, Bendis Investment Group LLC, Institute for Quantitative Biosciences (QB3), The BIG Health Consortium, Integra Foundation, BioAdvance, Juvenile Diabetes Research Foundation, Biogen Idec Innovation Incubator (bi3), Johnson & Johnson, Biotechonomy LLC, MedImmune Ventures, CIMIT (Center for Integration of Medicine and Innovative Technology), Merck, Cephalon, Multiple Myeloma Research Foundation, Charité Foundation, Myelin Repair Foundation, The Cleveland Clinic, National Pharmaceutical Council, Crohn’s & Colitis Foundation of America, National Cancer Institute, Cure Alzheimer's Fund, PKD Foundation, Cystic Fibrosis Foundation, Pfizer, Ernst & Young, Pure Tech Ventures, Ewing Marion Kauffman Foundation, Quaker BioVentures, Excel Medical Ventures, Regenerative Medicine Foundation, Geisinger Ventures, Takeda Research Investment, Hamner Institutes for Life Sciences, The Leukemia & Lymphoma Society, Hepatitis B Foundation and the Michael J. Fox Foundation, among others.
The Alliance Forum features Juan Enriquez, managing director of Excel Medical Ventures, as the keynote luncheon speaker and the presentation of the $100,000 Anthony J. Drexel Exceptional Achievement Award, honoring researchers in translational medicine, among the program highlights.
As space is limited, immediate registration is recommended at www.TranslationalMedicineAlliance.org.
Questions about the Alliance Forum can be directed to Info@TranslationalMedicineAlliance.org.
About the Kauffman Innovation Network
The not-for-profit Kauffman Innovation Network, Inc., (KIN) was created by the Ewing Marion Kauffman Foundation to advance innovations through education about best practices, research, and fellowships.